The World’s First Pre-loaded, Dry-packaged TAVR System Approved by NMPA

On April 9, 2025, KingstronBio received approval from China’s National Medical Products Administration (NMPA) for its ProStyle A® Transcatheter Aortic Valve Replacement (TAVR) System. This approval is a significant milestone, as it introduces the world’s first pre-loaded, dry-packaged TAVR system, representing a major technological advancement in the field of structural heart disease intervention.

Key Technical and Clinical Differentiators

The ProStyle A® system distinguishes itself with three core innovations designed to enhance procedural efficiency and long-term valve durability:

1. Dry Valve Technology: Unlike traditional valves stored in glutaraldehyde solution, the ProStyle A® utilizes a proprietary Micro-Ex anti-calcification platform. This nanotechnology-based process removes tissue debris and seals off calcification sources, thereby mitigating long-term calcification risk and contributing to an expected valve lifespan exceeding 15 years.
2. Pre-mounted Design: The valve is factory-mounted on its delivery system, eliminating the need for complex, time-consuming intraoperative assembly. This streamlined process reduces preoperative preparation time to under 5 minutes and minimizes the potential for procedural error.
3. Low-Profile and Adaptable Delivery: Featuring a small 18F outer diameter (equivalent to 14Fr/16Fr), the system’s flexible arch-crossing design and ultra-smooth coating enable navigation through challenging anatomies, including tortuous vessels, small-angle aortic arches, and horizontal hearts.

Clinical Outcomes and Performance Metrics

Clinical trials demonstrated robust performance, particularly in a cohort with a high percentage (approximately 50%) of patients with bicuspid valves. Key results include:

• Hemodynamic Performance: A post-procedural mean aortic valve pressure gradient of 12 mm Hg, indicating excellent flow characteristics.
• Procedural Safety: A low pacemaker implantation rate of 10.4%, which is 2.2 percentage points lower than the reported industry standard of 12.6%.
• Long-Term Durability: A 3-year follow-up study with a 95% retention rate reported zero new incidences of stroke, myocardial infarction, or reoperation, confirming the valve’s stability and durability.

Disclaimer: The information on this platform is for informational purposes only and is based on publicly available sources, such as official press releases and regulatory databases. While we strive for accuracy, details may vary from the manufacturer’s official statements, particularly if they have been translated. We encourage readers to consult the manufacturer’s official website and communications for the most current and accurate information. This report is not a substitute for professional medical advice, diagnosis, or treatment and does not constitute an endorsement of any product or company. We do not accept responsibility for any errors, omissions, or actions taken based on the information provided.